Hong Kong Nasopharyngeal Cancer Study Group Limited

Quick facts

Phase 2 pipeline

• Docetaxel, Cisplatin, 5-FU and Cetuximab · Oncology
  Docetaxel inhibits microtubule dynamics, Cisplatin induces DNA crosslinks, 5-FU inhibits thymidylate synthase, and Cetuximab binds to the epidermal growth factor receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Hong Kong Nasopharyngeal Cancer Study Group Limited portfolio CI brief
• Hong Kong Nasopharyngeal Cancer Study Group Limited pipeline updates RSS